Gulf War Illness vs POTS: symptoms, biomarkers, trials and researchliterature-only comparison
A data-driven comparison of Gulf War Illness and Postural Orthostatic Tachycardia Syndrome (POTS) built from the Open Source Medicine Foundation biomarker atlases, PubMed literature feeds, ClinicalTrials.gov registry extract and post-acute infection syndrome (PAIS) cohort database.
Autonomic abnormalities, including blunted heart-rate variability and orthostatic symptoms, are a recurring finding in GWI, which makes POTS a relevant phenotype to compare even though no GWI-specific POTS trials exist.
No biomarker atlas exists for POTS, so the biomarker sections below are limited to the other condition. This page compares literature, trials, therapeutics and cohorts.
What each condition is
Gulf War Illness
Also known as: GWI, Gulf War Syndrome, Chronic Multisymptom Illness
Gulf War Illness is a chronic multisymptom condition affecting roughly a quarter to a third of the nearly 700,000 US and allied personnel deployed in the 1990-1991 Gulf War. It is defined by the Kansas or CDC criteria (fatigue, pain, cognitive and mood symptoms, gastrointestinal and respiratory complaints) rather than by a single exposure, though pyridostigmine bromide, pesticides and low-level nerve agents are the leading hypotheses. Unlike the other conditions compared here it has no infectious trigger, which makes its biomarker overlap with post-viral syndromes scientifically interesting.
Atlas scope: Inflammatory, autoimmune, metabolic, cholinergic, and exposure-related biomarker alterations in Gulf War Illness (GWI / chronic multisymptom illness) compared to healthy deployed and non-deployed Gulf War veterans.
OSMF resources: biomarker atlas · literature feed
Postural Orthostatic Tachycardia Syndrome
Also known as: Postural tachycardia syndrome, Dysautonomia
POTS is a disorder of the autonomic nervous system defined by a sustained heart-rate rise of at least 30 beats per minute (40 in adolescents) within ten minutes of standing, without orthostatic hypotension, together with chronic orthostatic symptoms. It is a diagnosis made by tilt-table or active-stand testing rather than a blood test. POTS commonly follows infection, including COVID-19, and overlaps heavily with ME/CFS and Long COVID; OSMF tracks it through a literature feed and clinical-trial registry rather than a dedicated biomarker atlas.
OSMF resources: literature feed
Side-by-side summary
| Measure | Gulf War Illness | POTS |
|---|---|---|
| Biomarkers catalogued | 41 | No atlas |
| Biomarker categories covered | inflammatory (10), metabolic (8), exposure (7), autoimmune (5), neurological (4), functional (3), autonomic (2), ocular (2) | — |
| Markers with LOINC codes | 12 | — |
| Literature studies tracked | 75 | 75 |
| Most recent tracked study | 25 Jun 2026 | 09 Jul 2026 |
| Registered trials (all statuses) | 4 | 88 |
| Recruiting / not yet recruiting | 0 | 30 |
| Active, not recruiting | 0 | 13 |
| Completed | 4 | 33 |
| Terminated / withdrawn / suspended | 0 | 7 |
| Unknown status | 0 | 5 |
| Named cohorts in PAIS database | 0 | 0 |
| Therapeutic agents tracked | 10 | 128 |
Trial condition matching: Gulf War Illness uses keyword matching on registry condition and title fields; POTS uses keyword matching on registry condition and title fields. Trials listing both conditions: 0.
Biomarkers catalogued for Gulf War Illness
POTS has no OSMF biomarker atlas, so no shared-marker matching is possible. The Gulf War Illness atlas lists 41 markers; the 15 most relevant to this comparison are shown (autonomic, immune, inflammatory and vascular categories first).
- Heart rate variability (HRV) Decreased autonomic
- Orthostatic heart rate increment Increased autonomic
- C-Reactive Protein (CRP) Increased inflammatory
- Tumor Necrosis Factor-α (TNF-α) Increased inflammatory
- Interleukin-6 (IL-6) Increased inflammatory
- Interleukin-1β (IL-1β) Increased inflammatory
- Interleukin-8 (IL-8 / CXCL8) Increased inflammatory
- Neopterin Increased inflammatory
- sCD26 (soluble DPPIV) Mixed / conflicting inflammatory
- sCD14 Increased inflammatory
- Interferon-γ (IFN-γ) Increased inflammatory
- H3K9Ac (chromatin marker) Mixed / conflicting inflammatory
- Laser-induced blood spectra (LIBS) Mixed / conflicting functional
- 6-minute walk distance Decreased functional
- SF-36 physical component score Decreased functional
Browse the full Gulf War Illness atlas.
Overlapping therapeutics under investigation (1)
Agents that appear in registered trials or the OSMF therapeutic-agent database for both Gulf War Illness and POTS. Inclusion means an agent is being studied, not that it works.
- Coenzyme Q10 (CoQ10)
Recent research
Latest Gulf War Illness studies
Latest POTS studies
Frequently asked questions
Can you have both Gulf War Illness and POTS?
Yes. POTS is a syndrome diagnosed on clinical criteria and can be diagnosed in someone who also has Gulf War Illness; 0 registered trials in the OSMF registry list both conditions, and they share 1 therapeutic agent under investigation.
How do the biomarker profiles differ?
OSMF does not maintain a biomarker atlas for POTS, which is diagnosed by physiological or clinical criteria rather than a laboratory panel, so this is a literature-level comparison. Gulf War Illness has 41 catalogued markers across 8 categories (most often inflammatory, metabolic, exposure).
Which has more active clinical trials?
POTS has more: 43 active or recruiting trials versus 0 for Gulf War Illness (registry snapshot 07 Oct 2026). Totals including completed, terminated and unknown-status studies are 4 for Gulf War Illness and 88 for POTS. Condition matching for Gulf War Illness, POTS relies on keyword matching of registry condition fields and may miss trials. Trial counts measure research attention, not treatment efficacy.
Which condition has more recent research?
OSMF tracks 75 recent PubMed-indexed studies for Gulf War Illness (latest 25 Jun 2026) and 75 for POTS (latest 09 Jul 2026). The feeds hold a rolling window of recent publications, so they indicate current publication pace rather than lifetime output. See the Gulf War Illness feed and the POTS feed for the full lists.
Are the same treatments being studied for both?
1 agent appear in the trial registry or therapeutic-agent database for both conditions, including Coenzyme Q10 (CoQ10). All of these are investigational for these indications; none is an approved treatment for either condition. Overlap usually reflects shared hypotheses (immune modulation, autonomic support, antiviral or anti-inflammatory strategies) rather than demonstrated efficacy.
Which has larger research cohorts?
The PAIS cohort database lists 0 named cohorts for Gulf War Illness and 0 named cohorts for POTS. Cohorts with stored biospecimens and open external access are the most useful for cross-condition biomarker validation.
Related comparisons
Cite this page
@misc{osmf_gulfwarillness_vs_pots,
author = {Open Source Medicine Foundation},
title = {Gulf War Illness vs POTS: symptoms, biomarkers, trials and research compared},
year = {2026},
howpublished = {\url{https://research.opensourcemed.info/compare/gulf-war-illness-vs-pots.html}},
note = {Data as of 2026-10-07}
}Get OSMF research updates
New biomarker, trial and cohort data, summarised for patients and researchers.
Last updated 07 Oct 2026 (page build). Underlying data: literature feeds 09 Jul 2026 / 10 Jul 2026; trial registry 07 Oct 2026; atlases 29 Jun 2026 / n/a. Generated by scripts/build_compare_pages.py.